|
Largest study to date reveals baseline findings for flexible sigmoidoscopy
July 06, 2005The largest study to date on the early detection of colorectal cancer offers benchmark data for what could be expected from large-scale use of flexible sigmoidoscopy as a screening tool for colorectal cancer. The report, published in the July 6 issue of the Journal of the National Cancer Institute (JNCI), is part of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, a randomized, community-based longitudinal study evaluating the effectiveness of cancer screening tests on site-specific mortality.
"In our opinion, we now have published important and valuable baseline data on the use of flexible sigmoidoscopy within a large and randomized group of participants," said Joel Weissfeld, M.D., M.P.H, lead author of the study and associate professor of epidemiology, University of Pittsburgh Graduate School of Public Health. "The findings reveal trends and patterns by gender and age that one may expect to see in a flexible sigmoidoscopy intervention targeting the general U.S. population," added Dr. Weissfeld, who also is co-leader of the cancer epidemiology, prevention and control program at the University of Pittsburgh Cancer Institute.
During flexible sigmoidoscopy (FSG), a doctor uses a lighted scope to examine the inside of the large intestine from the rectum through the descending colon, where most colon polyps develop.
The study enrolled 154,942 men and women 55 to 74 years of age who had no prior history of prostate, lung, colorectal or ovarian cancers from November 1993 to July 2001. Study participants were randomly assigned to either a control group that did not receive FSG or to an intervention group that received FSG. Of those assigned to the intervention group, 83.5 percent (64,658) agreed to undergo an initial FSG examination. Among the individuals who underwent screening, 23.4 percent (15,150) had at least one polyp or mass and 74.2 percent of these individuals received follow-up lower endoscopic procedures. Findings also indicated that women were more likely to decline FSG than men, 19.2 percent and 13.8 percent respectively, and that non-acceptance of FSG increased with age among women, but not among men. The rate of cancer detected was 2.9 per 1,000 individuals screened.
"These data are important because they create a U.S. benchmark to which other studies can be compared," said Robert E. Schoen, M.D., M.P.H., study co-author and associate professor of medicine and epidemiology, University of Pittsburgh School of Medicine. "Of note is that a high percentage of study participants were willing to undergo flexible sigmoidoscopy, perhaps reflecting a growing acceptance of screening for colorectal cancer."
Colorectal cancer is a worldwide public health problem. In the United States, colorectal cancer accounts for 11 percent of all cancers, with 145,290 new cases and 56,290 deaths expected in 2005. For patients with advanced disease, five-year survival rates are 10 to 20 percent. When colorectal cancer is diagnosed at an early, localized stage, the five-year survival rate is 90 percent.
University of Pittsburgh Medical Center
The study enrolled 154,942 men and women 55 to 74 years of age who had no prior history of prostate, lung, colorectal or ovarian cancers from November 1993 to July 2001. Study participants were randomly assigned to either a control group that did not receive FSG or to an intervention group that received FSG. Of those assigned to the intervention group, 83.5 percent (64,658) agreed to undergo an initial FSG examination. Among the individuals who underwent screening, 23.4 percent (15,150) had at least one polyp or mass and 74.2 percent of these individuals received follow-up lower endoscopic procedures. Findings also indicated that women were more likely to decline FSG than men, 19.2 percent and 13.8 percent respectively, and that non-acceptance of FSG increased with age among women, but not among men. The rate of cancer detected was 2.9 per 1,000 individuals screened.
"These data are important because they create a U.S. benchmark to which other studies can be compared," said Robert E. Schoen, M.D., M.P.H., study co-author and associate professor of medicine and epidemiology, University of Pittsburgh School of Medicine. "Of note is that a high percentage of study participants were willing to undergo flexible sigmoidoscopy, perhaps reflecting a growing acceptance of screening for colorectal cancer."
Colorectal cancer is a worldwide public health problem. In the United States, colorectal cancer accounts for 11 percent of all cancers, with 145,290 new cases and 56,290 deaths expected in 2005. For patients with advanced disease, five-year survival rates are 10 to 20 percent. When colorectal cancer is diagnosed at an early, localized stage, the five-year survival rate is 90 percent.
University of Pittsburgh Medical Center
Colorectal Cancer News and Current Colorectal Cancer Events RSSFirst worldwide analysis of cancer survival finds wide variation between countries
Cancer survival varies widely between countries according to a worldwide study published online today in Lancet Oncology.* More than 100 investigators contributed to the study.
'Smothered' genes combine with mutations to yield poor outcome in cancer patients
Johns Hopkins Kimmel Cancer Center researchers have identified a set of genes in breast and colon cancers with a deadly combination of traditional mutations and "smothered" gene activity that may result in poor outcomes for patients.
Protein thought to promote cancer instead functions as a tumor suppressor, researchers report
A protein previously thought to promote colorectal cancer instead suppresses the growth of human cancer cells in culture, researchers at UT Southwestern Medical Center have found.
Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show
Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease.
Study evaluates factors associated with racial disparities in colon cancer screening
Blacks and Hispanics appear less likely to undergo colorectal cancer screening than whites because of socioeconomic, health care access and language barriers, according to a report in the June 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. However, other factors may contribute to screening disparities experienced by Asians.
Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis
Cancer patients with low socioeconomic status (SES) have more advanced cancers at diagnosis, receive less aggressive treatment, and have a higher risk of dying in the five years following cancer diagnosis, according to a new study.
MIT researchers see alternative to common colorectal cancer drug
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.
Obese women in Canada are less likely to be screened for cervical cancer
Research in the United States has shown that obese people are less likely than their normal-weight peers to undergo screening for breast, colon and cervical cancer. Raj Padwal, Rebecca Mitchell and Scott Klarenbach, from the University of Alberta's Faculty of Medicine & Dentistry, have undertaken a study to see if this trend is also true in Canada.
Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s
The prevalence of pre-cancerous masses in the colon is the same for average-risk patients who are 40 to 49 years of age and those who are 50 to 59 years of age.
More Colorectal Cancer News Articles
| © 2008 BrightSurf.com |